Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients

• Status: Withdrawn
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether eplerenone is effective in the treatment of blood pressure, heart function, renal function in elderly hypertensive stage1 (eGFR>=90ml/min/1.73m2) and stage2 (eGFR 60-89ml/min/1.73m2) chronic kidney disease (CKD) patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jichi Medical University
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

• Clinical diagnosis of stage1(eGFR>=90ml/min/1.73m2) and stage2 (eGFR 60- 89ml/min/1.73m2)chronic kidney disease

• Clinical diagnosis of Hypertension (Blood pressure >=140/90mmHg)

• Elderly people(>=65 years old)

Exclusion Criteria:

• The patients who are already taking eplerenone

• Stage3(eGFR 30-60 ml/min/1.73m2),stage4(eGFR 15-30 ml/min/1.73m2)and stage5 (eGFR <15 ml/min/1.73m2) CKD patients

• The patients who are receiving hemodialysis or peritoneal dialysis

• The patients who are taking itraconazole, ritonavir and nelfinavir

• The patients who are taking potassium-sparing diuretics and potassium supplement

• The patients who have hyperkalemia(>=5.5mEq/ml)

• Severe heart failure (>=NYHA class III)

• Insulin dependent diabetic mellitus or poor controlled insulin independent diabetic mellitus (>=HbA1c 9.0&)

• Severe liver dysfunction (five folds increased AST or ALT than standard values)